Form 4: Ironwood CCO Sells Shares for Tax Obligations

Ironwood Pharmaceuticals' Chief Commercial Officer, Tammi L. Gaskins, sold over 21,000 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Tammi L. Gaskins, Chief Commercial Officer of Ironwood Pharmaceuticals, Inc. (IRWD), reported sales of Class A Common Stock.
• On February 23, 2026, 10,287 shares were sold at a weighted average price of $3.81 per share, with prices ranging from $3.70 to $4.05.
• On February 24, 2026, an additional 11,239 shares were sold at a weighted average price of $3.66 per share, with prices ranging from $3.60 to $3.73.
• These sales were non-discretionary, executed automatically to satisfy tax withholding obligations associated with the vesting of restricted stock units.
• Following these transactions, Tammi L. Gaskins beneficially owns 213,738 shares of Class A Common Stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly negative event. While the sale is non-discretionary for tax purposes, it still results in a reduction of insider ownership, which is generally not a positive signal, but also not indicative of a lack of confidence.

Negatives

• The total beneficial ownership of Class A Common Stock by the Chief Commercial Officer decreased by 21,526 shares.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sale reported represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common occurrence for executives receiving equity compensation. They are typically not viewed as a discretionary move by the insider to reduce their stake due to a lack of confidence in the company, but rather as a routine administrative event to manage tax liabilities arising from vested equity awards.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the non-discretionary nature mitigates concerns about management confidence.

Key Dates

Recommendation

The filing details a routine, non-discretionary 'sell to cover' transaction by a company officer for tax purposes. This type of insider sale typically does not signal a change in management's outlook or confidence in the company's future, nor does it provide new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as this event alone does not present a strong buy or sell signal for a seasoned investor.

Keywords

Ironwood Pharmaceuticals, IRWD, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, Officer Transaction